EDT Nektar (NKTR) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback